The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells

Breast Cancer Research and Treatment

Volumn 63, Issue 1, 2000, Pages 1-10

  Sundaram, S ^a,b   Chaudhry, M ^a   Reardon, D ^a,c   Gupta, M ^a   Gewirtz, D A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Adriamycin; Apoptosis; Breast tumor cells; EB 1089; Vitamin D

Indexed keywords

COLECALCIFEROL; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; SEOCALCITOL; SOMATOMEDIN BINDING PROTEIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CALCITRIOL; DRUG DERIVATIVE; MACROLIDE; RADIOSENSITIZING AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY; BREAST TUMOR; CELL CULTURE; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION; TUMOR SUPPRESSOR GENE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CALCITRIOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; GENES, P53; HUMANS; MACROLIDES; MITOGEN-ACTIVATED PROTEIN KINASES; POINT MUTATION; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0033626504     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006420708806     Document Type: Article

References (49)

1. Cancer of the breast: The past decade
2. The noncalcemic vitamin D analogues EB 1089 and 2-oxacalcitriol interact with vitamin D receptor and suppress parathyroid hormone-related gene expression
3. Vitamin D analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia
4. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen
5. Combined effects of 1,25 dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells
6. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
7. 1,25-Dihyroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage
8. The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation
9. The influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumor cell lines differing in p53 status
10. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
11. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells
12. Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response
13. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA damaging agents
14. P53 dependent apoptosis modulates the cytotoxicity of anticancer agents
15. p53 Status and the efficacy of cancer therapy in vivo
16. Growth arrest and non-apoptotic cell death associate with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin
17. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin
18. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation
19. Factors affecting topotecan induced programmed cell death: Adhesion protects cells from apoptosis and impairs cleavage of Poly(ADP-ribose-polymerase
20. Normal p53 status and function despite the development of drug resistance in human breast cancer cells
21. Transcriptional activation by p53 but not induction of the p21 gene is essential for oncogene mediated apoptosis
22. P21 waf1/cip 1 protects against p53 mediated apoptosis of human melanoma cells
23. p53 Expression overcomes p21waf1/cip1 mediated G1 arrest and induces apoptosis in human cancer cells
24. Roles for basal and stimulated p21 (Cip-1/Waf1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells
25. Ras induces p21 waf1/cip1 cyclin kinase inhibitor transcriptionally through SP1-binding sites
26. Ras and mitogen-activated protein kinase dependent and independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor and transforming growth factor
27. 1 Alpha 25-dihydroxy vitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines
28. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells
29. Combined effect of vitamin D3 analogs and paclitaxel on growth of MCF-7 breast cancer cells in vivo
30. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB 1089
31. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
32. A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy associated hypercalcemia in vivo
33. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
34. Dual modes of cell death induced by etoposide in human epithelial tumor cells allow Bc1-2 to inhibit apoptosis without affecting clonogenic survival
35. p53 Status affects the rate of onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-myc
36. Caspase 3 is required for DNA fragmentation and morphological changes associated with apoptosis
37. Cell death: Programmed, apoptosis, necrosis or other
38. Comparison of methods based on Annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells
39. RAR alpha antagonist RO-41-5253 inhibits proliferation and induces apoptosis in breast cancer cell lines
40. Involvement of microtubules in the regulation of Bc1-2 phosphorylation and apoptosis through cyclic AMP dependent protein kinase
41. Tamoxifen induces TGF-Beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro
42. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3' kinase and mitogen activated protein kinase pathways
43. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3 kinase and Akt
44. The P13 kinase/Akt signaling pathway delivers an anti-apoptotic signal
45. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein 3 (IGFBP-3) in breast cancer cells
46. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery
47. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen activated protein kinase pathway
48. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3